Entera Bio announced an additional presentation at the ASBMR 2026 Annual Meeting to showcase the Phase 3 study design for EB613, its oral anabolic tablet for osteoporosis treatment. The study, led by Dr. Felicia Cosman, will be a randomized, double-blind, placebo-controlled trial focusing on postmenopausal women with osteoporosis. This follows positive Phase 2 results showing EB613's effectiveness in increasing bone density and markers of bone formation without significant safety concerns. The Phase 3 trial aims to further validate EB613 as the first oral anabolic treatment option for osteoporosis, potentially transforming patient care by offering a convenient alternative to injectable therapies.
Entera Bio's announcement of an additional presentation on its EB613 Phase 3 study design provides context for readers interested in health sector developments. For readers following Health-sector US stocks on Pluang, here is the market snapshot as of Oct 08, 2026 18:43 WIB: out of 128 priced stocks, 29 rose and 91 fell. Notable movers include MMED at USD 19.11 with a 1-day change of -2.70%, HRTX at USD 0.38 with a 1-day change of -2.56% and a typical hold time of 35 days with Pluang order activity showing 30% Sell and 70% Buy, and WGS at USD 67.00 with a 1-day change of -2.23%, typical hold time 19 days, and Pluang order activity 47% Sell / 53% Buy.
MIND, an AI-native data loss prevention (DLP) platform, was named "Data Loss Prevention Platform of the Year" in the 2026 CyberSecurity Breakthrough Awards. The platform uses advanced AI to discover, detect, and prevent sensitive data leaks across va...
The global Mivan construction market is projected to grow from $3.92 billion in 2025 to $7.05 billion by 2031, at a CAGR of 10.28%. Growth is fueled by demand for rapid mass housing, affordable residential projects, and faster construction enabled by...
RBC Capital has increased its price target for Amgen from $400 to $430, reflecting strong confidence in the biopharmaceutical company's future performance. Amgen's stock has outperformed both the S&P 500 and the broader medical sector recently, suppo...
Tilray Brands reported a wider-than-expected loss of $0.32 per share for Q1 fiscal 2027, missing revenue estimates with $257.1 million, though revenue grew 23% year-over-year. The company achieved record first-quarter gross profit with a 30% gross ma...
UnitedHealth Group is expected to report Q3 earnings of $4.12 per share on $111.3 billion revenue, with investors closely watching medical cost trends and Medicare Advantage membership. The company improved its medical care ratio and operating earnin...
